Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2011

View Archived Issues

Four-marker signature exhibits improved prognostic accuracy in prostate cancer progression

Azacitidine has dual mechanism of action in resistant cancer cells

PTC Therapeutics achieves first milestone in BMI-1 collaboration with Wellcome Trust

BioDelivery Sciences announces results of FDA meeting on BEMA-delivered buprenorphine/naloxone

Novel HCV NS3/NS4A inhibitors patented by Idenix

Novel IAP inhibitors for treatment of cancer designed at Takeda

Servier presents new anticancer dihydroindolone analogues

Infinity Pharma's IPI-926 enters phase II trial and receives FDA orphan status in chondrosarcoma

Noscira presents new inhibitors of beta-secretase 1 and Abeta production

Kissei claims new catechol O-methyltransferase inhibitors

French scientists present new CK II inhibitors

FDA clears Palatin Technologies' IND for phase IIa PL-3994 trial in asthma

Cempra Pharma provides pipeline update on solithromycin and Taksta

InterMune receives approval for Esbriet in Europe

Endo Pharma launches Fortesta testosterone gel in U.S.

Novel TGFR-2-based trap T22d35 reduces tumor growth in vivo

ACT Biotech files SPA with FDA for phase III telatinib trial

Lycera and Merck & Co. enter into autoimmune treatment collaboration

AGS-004 delays rebound of HIV during interruption of antiretroviral therapy

Phase III ORAL Sync trial of Pfizer's tofacitinib meets primary endpoints

FDA approves removal of boxed warning regarding liver injury from Letairis label

European Commission approves Firazyr self-administration label for HAE

Ziopharm grants exclusive license to Solasia for Zinapar in Asia

Vical and EMA reach agreement on endpoints for pivotal phase III trial of TransVax vaccine

MediciNova and Zhejiang Medicine form partnership for MN-221 in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...